close

Fundraisings and IPOs

Date: 2011-10-17

Type of information: Series A financing round

Company: Hoopika Biotech (Austria)

Investors: Sofinnova Partners (France) Forbion Capital Partners (The Netherlands)

Amount: €7 million

Funding type: series A financing round

Planned used:

Hookipa Biotech is a biotech startup company founded in July 2011 in Austria. The company utilizes its proprietary Vaxwave™ technology platform to develop genetic vaccines for the prophylactic and therapeutic treatment of diseases. Vaxwave™ introduces a new approach to vaccination by providing long lasting and potent stimulation of both cellular and humoral immunity; the platform has been validated in different disease models. The company will use the Series A funds to advance its lead product HB101 through pre-clinical development and a Phase I proof of concept study, and to further industrialize and validate the Vaxwave™ technology.

Others:

* On October 17, 2011, Hookipa Biotech, a startup biotech company specialized in developing new generation vaccines, announced that it has raised €7 million Series A financing led by Sofinnova Partners. Forbion Capital Partners joined the syndicate as the co-investor.

Therapeutic area: Cancer - Oncology - Infectious diseases

Is general: Yes